FDA Approves Tecentriq for First-Line Treatment of Metastatic NSCLC with High PD-L1 Expression
May 19, 2020
On May 18th, 2020, the Food and Drug Administration (FDA) approved Tecentriq (atezolizumab) for the first line treatment of advanced non-small cell lung cancer (NSCLC) with tumors having high expressions of PD-L1 (>50%) and no changes in EGFR or ALK. The FDA based their approval on the results of the clinical trial IMpower-110 which showed that patients receiving Tecentriq (atezolizumab) lived longer, had a higher chance of responding well to treatment, and went longer periods of time without progression than those receiving chemotherapy.Tecentriq (atezolizumab) being available as a first line immunotherapy option for NSCLC gives patients more options for first line treatments than ever before.Click here to read the full press release.
Lung cancer questions? Contact our free HelpLine at support@go2.org or 1-800-298-2436.